Balasa Dinverno & Foltz LLC Regeneron Pharmaceuticals, Inc. Transaction History

Balasa Dinverno & Foltz LLC

$1.58 Billion
Q3 2022

A detailed history of Balasa Dinverno & Foltz LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Balasa Dinverno & Foltz LLC holds 1,822 shares of REGN stock, worth $1.93 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,822

Previous 1,687 8.0%

Holding current value

$1.93 Million

Previous $997,000 25.88%

% of portfolio

0.08%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$573.97 - $724.32 $77,485 - $97,783	135 Added 8.0%	1,822 $1.26 Million
Q2 2022 Aug 09, 2022	SELL	$548.35 - $738.84 $47,158 - $63,540	-86 Reduced 4.85%	1,687 $997,000
Q1 2022 Apr 25, 2022	BUY	$595.12 - $698.43 $233,882 - $274,482	393 Added 28.48%	1,773 $1.24 Million
Q4 2021 Jan 26, 2022	BUY	$543.48 - $670.97 $335,327 - $413,988	617 Added 80.87%	1,380 $871,000
Q3 2021 Oct 26, 2021	BUY	$574.03 - $680.96 $121,694 - $144,363	212 Added 38.48%	763 $462,000

Q2 2021 Jul 23, 2021	SELL	$472.8 - $558.54 $43,024 - $50,827	-91 Reduced 14.17%	551 $308,000
Q1 2021 Apr 29, 2021	SELL	$446.73 - $548.2 $451,644 - $554,230	-1,011 Reduced 61.16%	642 $304,000
Q4 2020 Jan 26, 2021	SELL	$478.3 - $607.98 $406,555 - $516,783	-850 Reduced 33.96%	1,653 $799,000
Q3 2020 Nov 10, 2020	SELL	$544.75 - $658.21 $9,805 - $11,847	-18 Reduced 0.71%	2,503 $1.4 Million
Q2 2020 Aug 07, 2020	BUY	$493.32 - $643.92 $996,013 - $1.3 Million	2,019 Added 402.19%	2,521 $1.57 Million
Q1 2020 Apr 30, 2020	BUY	$336.18 - $494.43 $168,762 - $248,203	502 New	502 $245,000

Others Institutions Holding REGN

# of Institutions

1,425

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $113B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balasa Dinverno & Foltz LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balasa Dinverno & Foltz LLC with notifications on news.

Account

Balasa Dinverno & Foltz LLC Regeneron Pharmaceuticals, Inc. Transaction History